Clinical Trials Browser

Phase 1 × Ureteral Neoplasms × enfortumab vedotin × Clear all

NCT04963153 2026-03-18

Testing Combination Erdafitinib and Enfortumab Vedotin in Metastatic Bladder Cancer After Treatment With Chemotherapy and Immunotherapy

Phase 1 Active not recruiting

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Ureteral Neoplasms, Urethral Neoplasms